?Emergent BioSolutions (EBS) Receives a New Order from US Department of War [Yahoo! Finance]
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
Inc. (NYSE:EBS) announced receiving an order worth up to $21.5 million from the US Department of War. ?Management noted that the order entails the supply of BioThrax, which is the company's primary product for anthrax protection, primarily for military personnel at high risk of exposure. Deliveries are expected to occur throughout 2026 with a one-year base period and optional extensions into 2027 and 2028. Management also highlighted that BioThrax remains the only FDA-approved anthrax vaccine, and the latest order aligns with the company's ongoing role in providing vaccines for US defense needs against biological threats. ?That said, on the same day, Emergent BioSolutions Inc. (NYSE:EBS) announced its collaboration with PANTHER to fund the ongoing “MpOx Study in Africa, which is an Africa CDC-led trial testing potential treatments for Mpox. Safety data from the first 50 randomized patients were collected in December, and the trial was cleared to proceed without any issues. Managem
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- New York Sues Former C.E.O. of Covid Vaccine Maker Over Insider Trading [The New York Times]The New York Times
- Former biotech CEO sued over COVID vaccine alleged insider trading [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday PreparednessGlobeNewswire
- Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year TransformationGlobeNewswire
- Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026GlobeNewswire
EBS
Earnings
- 10/29/25 - Beat
EBS
Analyst Actions
- 12/16/25 - HC Wainwright
EBS
Sec Filings
- 1/14/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/7/26 - Form 144
- EBS's page on the SEC website